CapsoVision (NASDAQ:CV) Issues Earnings Results

CapsoVision (NASDAQ:CV) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, FiscalAI reports. The company had revenue of $2.79 million for the quarter.

Here are the key takeaways from CapsoVision’s conference call:

• CapsoVision said underlying utilization remains strong, with deeper engagement in existing accounts and continued growth in end-user consumption of CapsoCam Plus across its installed base.
• The company expects a meaningful near-term catalyst from AI Highlights, its AI-assisted reading feature for CapsoCam Plus, with FDA clearance anticipated around mid-year and a commercial launch shortly after.
• Management highlighted progress across the pipeline, including CapsoCam Colon Gen Two remaining on track for submission in the third quarter of 2026 and enrollment beginning in the pancreatic cancer clinical study.
• First-quarter revenue was $2.8 million, flat year over year, while gross margin declined to 48% from 54% due mainly to tariffs affecting cost of goods sold.
• Operating expenses rose to $8.4 million as the company increased investment in R&D and clinical trials, but CapsoVision ended the quarter with $17.9 million in cash after a $14 million private placement in March.

CapsoVision Price Performance

CV traded down $0.27 on Friday, hitting $7.03. The company had a trading volume of 21,201 shares, compared to its average volume of 329,847. The stock has a market cap of $350.60 million and a price-to-earnings ratio of -3.20. The company’s fifty day moving average price is $6.45 and its 200 day moving average price is $6.73. CapsoVision has a 1-year low of $3.43 and a 1-year high of $15.37.

Wall Street Analysts Forecast Growth

Separately, Benchmark cut their price target on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating on the stock in a report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Hedge Funds Weigh In On CapsoVision

A number of institutional investors have recently modified their holdings of CV. Deutsche Bank AG acquired a new stake in shares of CapsoVision in the fourth quarter worth $47,000. Wells Fargo & Company MN grew its stake in CapsoVision by 66.4% in the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after buying an additional 2,508 shares during the last quarter. New York State Common Retirement Fund bought a new position in CapsoVision in the 3rd quarter worth $34,000. Virtu Financial LLC acquired a new position in CapsoVision during the 4th quarter worth $128,000. Finally, Millennium Management LLC acquired a new position in CapsoVision during the 4th quarter worth $163,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.